ASX ANNOUNCEMENT

BENITEC INVESTOR PRESENTATION

Sydney, 5 August 2014: Benitec Biopharma Limited (ASX: BLT) (OTC: BTEBY) is pleased to release a copy of the presentation that Dr David Suhy, Senior VP Research & Development, will be delivering to investors during a non-deal roadshow in Melbourne and Sydney.

The presentation highlights Benitec’s progress on the company’s ddRNAi programs and provides an update on Phase I/IIa Hepatitis C trials.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

<table>
<thead>
<tr>
<th>Company</th>
<th>Investor relations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Stubbings</td>
<td>Jane Lowe</td>
</tr>
<tr>
<td>Chief Business Officer</td>
<td>Buchan Consulting</td>
</tr>
<tr>
<td>Tel: +61 (2) 9555 6986</td>
<td>Tel: +61 (2) 9237 2807</td>
</tr>
<tr>
<td>Email: <a href="mailto:cstubbings@benitec.com">cstubbings@benitec.com</a></td>
<td>Email: <a href="mailto:jlowe@buchanwe.com.au">jlowe@buchanwe.com.au</a></td>
</tr>
</tbody>
</table>

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT, OTC: BTEBY) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAI. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington’s disease. For more information on Benitec refer to the Company’s website at www.benitec.com.
Benitec Biopharma:
“In it for the long haul”: Differentiating ddRNAi from its peers in the RNAi space

Dr David Suhy, PhD Senior VP Research & Development, Benitec Biopharma
August 2014
Forward looking statement

This presentation contains forward looking statements that involve risks and uncertainties.

Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Benitec Biopharma can give no assurance that these expectations will prove to be correct.

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction. Neither this presentation nor anything in it will form any part of any contract for the acquisition of securities.
RNAi...It’s simply about knocking down genes...

OR IS IT? What differentiates the Benitec ddRNAi Technology?

Non-specific shRNA

HCV shRNA-8

Firefly Luc shRNA
TT-034: Delivery to liver via AAV vector

TT-034: a ddRNAi construct in AAV that produces anti-HCV shRNA

TT-034 infused into the body preferentially binds to liver cells

TT-034 enters cell and homes in on nucleus

TT-034 delivers ddRNAi payload into nucleus

The cell’s own machinery makes a continuous, replenishing supply of therapeutic shRNAs against HCV
Utilization of viral vectors can permit exquisite tissue specific delivery

<table>
<thead>
<tr>
<th>animal</th>
<th>SSAN3 Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>dose</td>
<td>1.25 E12 vg/kg</td>
</tr>
<tr>
<td>copies per cell</td>
<td></td>
</tr>
<tr>
<td>TISSUE</td>
<td>mean</td>
</tr>
<tr>
<td>Liver-LT-Caudal</td>
<td>199.6</td>
</tr>
<tr>
<td>Liver-RT-Caudal</td>
<td>165.2</td>
</tr>
<tr>
<td>Liver-Medial</td>
<td>142.8</td>
</tr>
<tr>
<td>Spleen</td>
<td>23.7</td>
</tr>
<tr>
<td>LN-Inguinal</td>
<td>15.9</td>
</tr>
<tr>
<td>LN-Mandibular</td>
<td>13.2</td>
</tr>
<tr>
<td>Injection Site</td>
<td>7.3</td>
</tr>
<tr>
<td>Bone Marrow</td>
<td>3.4</td>
</tr>
<tr>
<td>LN-Mesenteric</td>
<td>2.5</td>
</tr>
<tr>
<td>Kidney</td>
<td>1.0</td>
</tr>
<tr>
<td>Heart-LT Ventricle</td>
<td>1.0</td>
</tr>
<tr>
<td>Heart-RT Ventricle</td>
<td>0.4</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0.3</td>
</tr>
<tr>
<td>Lung</td>
<td>0.3</td>
</tr>
<tr>
<td>Cecum</td>
<td>0.3</td>
</tr>
<tr>
<td>Jejunum</td>
<td>0.2</td>
</tr>
<tr>
<td>Heart-Septum</td>
<td>0.2</td>
</tr>
<tr>
<td>Ileum</td>
<td>0.1</td>
</tr>
<tr>
<td>Duodenum</td>
<td>0.1</td>
</tr>
<tr>
<td>Colon</td>
<td>0.1</td>
</tr>
<tr>
<td>Ovary</td>
<td>0.1</td>
</tr>
<tr>
<td>Brain-Diencephalon</td>
<td>0.1</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.0</td>
</tr>
<tr>
<td>Brain-cerebellum</td>
<td>0.0</td>
</tr>
<tr>
<td>Skeletal muscle</td>
<td>0.0</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>0.0</td>
</tr>
<tr>
<td>Thymus</td>
<td>0.0</td>
</tr>
<tr>
<td>Rectum</td>
<td>0.0</td>
</tr>
<tr>
<td>Brain-Funatal</td>
<td>0.0</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>Tissue NA</td>
</tr>
<tr>
<td>Adrenals</td>
<td>Tissue NA</td>
</tr>
<tr>
<td>LN-axillary</td>
<td>Tissue NA</td>
</tr>
</tbody>
</table>

Biodistribution Analysis: >90% into hepatic tissues

In Situ Hybridization analysis demonstrates near complete transduction and uniform expression of therapeutic sequences

For personal use only

Copyright © Benitec Biopharma Ltd, 2014
www.benitec.com
Flexibility in delivery platform to fit disease indication and tissue location

Viral Vectors
(HCV, HBV, Ocular, Pain, OPMD)

Nanoparticle delivery of minicircle DNA or mini-transcription cassettes

Nanoparticle delivery of DNA plasmids
(lung cancer)

Delivery of transduced cells expressing shRNA
### Tissues and/or cell types targeted in Benitec pipeline programs

<table>
<thead>
<tr>
<th>Focus</th>
<th>Indication</th>
<th>Partners / Collaborators</th>
<th>Discovery</th>
<th>Pre-clinical</th>
<th>Clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious Disease</td>
<td>Hepatitis C</td>
<td></td>
<td>LIVER</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis B</td>
<td>Biomics Biotechnology (JV)</td>
<td>LIVER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td>Non Small Cell* Lung Cancer</td>
<td>University of New South Wales (RC)</td>
<td>LUNG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer Associated Pain</td>
<td>Stanford University (RC)</td>
<td>CNS/NEURONAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ocular Disease</td>
<td>AMD**</td>
<td></td>
<td>EYE/RETINA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetic Disease</td>
<td>OPMD***</td>
<td>Royal Holloway London University (RC)</td>
<td>MUSCLE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RC = research collaboration  
JV = joint venture  
*and other chemotherapy-resistant cancers  
**Age-Related Macular Degeneration  
***Oculopharyngeal Muscular Dystrophy, an orphan disease
Expression of multiple therapeutic agents from a single vector

- 3 independently transcribed RNAi elements target 3 separate, well-conserved regions of the HCV genome; helps prevent the generation of viral escape mutants

- Combination drug in one therapeutic entity provides broad patient applicability, while maintaining specificity
Ability to regulate shRNA expression and quantify their expression in target tissues

Northern Blot Analysis

Custom QPCR Analysis
Ability to use next generation ddRNAi technologies to develop more efficient, safe drugs

**Characteristic:**

- Multi-targeting
- Lowered shRNA expression

**Drug (program):**

- TT-034 (HCV)
- TT-211 (Ocular)
- TT-231 (Ocular)

**Characteristics:**

- Tissue Restricted Expression
- Defined shRNA loop processing

**Diagram:**

- Anti-HCV shRNA-22
- Anti-HCV shRNA-19
- Anti-HCV shRNA-6
- Cell specific Promoter A
- VEGF-a shMiR
- General Pol III Promoter
- Target V
- Target P
- Target C
- ITR
- U6-9*
- U6-1*
- U6-8*
- ITN
Durability: Expression in hepatic tissues from a single IV administration

Levels of shRNA22 in murine hepatic tissues

60 days post dosing

180 days post dosing

ddRNAi HAS THE POTENTIAL TO DELIVER “ONE-SHOT CURES”
From bench to bedside: TT-034 regulatory path

• First shRNA-based RNAi therapeutic to be applied systemically using non-withdrawable viral vector in humans

• Program oversight by FDA (CBER), NIH OBA, EMA, MHRA, AFSSAPS, & Swiss Medic

• Being a first in class therapeutic, all agencies interested in learning how to regulate as well as providing regulatory guidance

• Favorable review at meeting at National Institutes of Health – Recombinant DNA Advisory Committee (RAC) June 2013

• No clinical hold after 30 day review of IND filing by FDA – ‘OK to proceed’ with trial was given January 15, 2014
**Benitec Biopharma Exclusive and Robust IP**

Exclusive license for the global development and commercialisation of human therapeutics using the unique and durable gene-silencing technology, ddRNAi

- 59 granted or allowed patents with more than 60 additional patents pending, including:

<table>
<thead>
<tr>
<th>Intellectual Property Summary</th>
<th>Details</th>
</tr>
</thead>
</table>
| Graham family patents:       | US 8067383, Granted November 2011  
US 8048670, Granted November 2011  
US 8053419, Granted November 2011  
US 8168774, Granted May 2012  
Europe 1555317, Issued January 2012; currently under opposition at the EPO*  
Europe 1624060, Issued January 2012; currently under opposition at the EPO* |
| Waterhouse family patents:   | Europe 1068311, Accepted April 2011, currently under opposition at the EPO* |
| Benitec Biopharma-owned patents: | Multi-promoter multi cassette: Europe 1725660, Granted May 2011  
Minigene Expression cassette: US 8129510, Granted March 2012 |

* part of the standard process for patent granting in Europe

- Benitec Biopharma’s has been challenged in a number of territories
  - All disputes have been overcome and patents reissued, with the exception of European patents undergoing a standard review
Although shRNA-directed RNAi is routinely practiced on the lab bench, only Benitec Biopharma has all of the necessary components for bringing it into the clinic.
Commercially focused management and board

Management
• MD and CEO: Peter French, MBA, PhD
  – CSIRO, St Vincent's,
  – Cryosite founder.
• CSO: Michael Graham, PhD
  – Inventor of ddRNAi technology
  – CSIRO, Benitec founder
• CBO: Carl Stubbings, BSc
  – Panbio, Quest Diagnostics, Focus Diagnostics
• SVP R&D: David Suhy, PhD
  – Tacere Therapeutics, Avocel, Antara Biosciences, PPD Discovery
• CFO: Greg West, CA
  – Price Waterhouse, Bankers Trust, Deutsche Bank, NZI

Board
Chairman:
• Peter Francis, LLB, Grad Dip. (Intellectual Property)
  – Partner at Francis Abourizk Lightowlers

Directors:
• John Chiplin, PhD
  – Polynoma, Arana, ITI Life Science Fund
• Iain Ross, BSc, CH.D.
  – Silence Therapeutics, Tissue Therapies, Ark Therapeutics
• Kevin Buchi
  – Cephalon, Teva, Mesoblast, Tetralogic

Key Recent Additions to the team:
• Terrie-Anne Cock, R&D Program Manager
• Sakura Holloway, Internal Patent Counsel
• Tin Mao, Senior Scientist
• Shih-chu Kao, Senior Scientist

www.benitec.com
TT-034 trial specifics

- An open label, single dose, dose escalation study in 14 patients infected with genotype 1 HCV
- Goal is to achieve complete and sustained elimination of virus with a single infusion
- Trial sites:
  - Duke Clinical Research Unit, North Carolina - currently dosing & continuing to screen additional patients
  - University of California, San Diego
Clinical trial endpoints

Primary endpoints: safety
• Incidence of treatment-emergent adverse effects
• Changes in clinical and laboratory parameters

Secondary endpoints: efficacy
• Sustained reduction in HCV viral load
• Assessment of shRNA expression in liver biopsy and serum exosomes
## Trial cohorts

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Dose (vg/kg)</th>
<th>Dose escalation step (log 10)</th>
<th>Total No subjects</th>
<th>Dosing scheme for subjects</th>
<th>Observation period per subject and between cohorts before dose escalation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$4.00 \times 10^{10}$</td>
<td>Starting dose</td>
<td>2</td>
<td>Sequential (1+1)</td>
<td>6 week</td>
</tr>
<tr>
<td>2</td>
<td>$1.25 \times 10^{11}$</td>
<td>0.5</td>
<td>3</td>
<td>Sequential and parallel (1+2)</td>
<td>6 week</td>
</tr>
<tr>
<td>3</td>
<td>$4.00 \times 10^{11}$</td>
<td>0.5</td>
<td>3</td>
<td>Sequential and parallel (1+2)</td>
<td>6 week</td>
</tr>
<tr>
<td>4</td>
<td>$1.25 \times 10^{12}$</td>
<td>0.5</td>
<td>3</td>
<td>Sequential and parallel (1+2)</td>
<td>10 weeks</td>
</tr>
<tr>
<td>5</td>
<td>$4.00 \times 10^{12}$</td>
<td>0.5</td>
<td>3</td>
<td>Sequential and parallel (1+2)</td>
<td>10 weeks</td>
</tr>
</tbody>
</table>

- DSMB review after first patient in each cohort and between cohorts
- Extensive safety monitoring during 24 weeks observation
Update on Phase I/IIa HCV trial:

First subject was dosed at Duke in Late May

No adverse safety events have been detected as a result of TT-034 dosing

A liver biopsy taken from the subject at Day 21 confirms:
- TT-034 has transduced liver cells of the subject
- TT-034 produced low levels of shRNA in the liver cells

DSMB (Data Safety Monitoring Board) recommends that the trial continue as planned

UCSD now active as a recruiting site
Key Inclusion Criteria:

1. Signed Informed Consent Form
2. $\geq$ 18 years old and $\leq$ 65 years of age
3. Females of non-childbearing potential
4. Males and their partners must be willing to comply with double barrier contraception
5. A history of chronic HCV genotype 1 infection with baseline HCV RNA level of $>100,000$ IU/mL, and one or more of the following:
   - Treatment failures or relapse to current SoC
   - Ineligible or unwilling to receive current SoC
6. No evidence of cirrhosis at screening
7. Alanine aminotransferase levels $\leq 4 \times$ the ULN
8. At least 3 months since prior therapy for HCV
1. Body mass index < 18.5 or > 30.
2. Serum Neutralizing Antibodies to AAV8 (may abrogate transduction)
3. Signs of severe liver disease
4. Hepatocellular carcinoma or suspicion of HCC
5. Positive for human immunodeficiency virus 1 (HIV1) or HIV2 antibody
6. Co-infection with hepatitis B virus
7. Treatment with an investigational drug within 6 months
8. Received an AAV vector at any time, or any other gene transfer agent in the previous 6 months
9. Use of immunosuppressive medications within 6 months before, except for inhaled or topical corticosteroids.
Thank you